

Impact of Distributing an Opioid Safety Guide at Prescription Pick Up

S.W. Champaloux PhD, MPH¹, M.S. Taitel, PhD², S. McClelland, PharmD³, P.P. Gleason, PharmD^{1,4}. ¹Prime Therapeutics LLC, Eagan, MN, United States; ²Walgreen Co., Deerfield, IL, United States; ³Florida Blue, Jacksonville, FL, United States; ⁴University of Minnesota, College of Pharmacy, Minneapolis, MN, United States.

No external funding provided for this research.

Background

- Opioid overdose deaths continue to rise in the United States.¹
- The U.S. Surgeon General encourages high-dose opioid utilizers to have the opioid overdose reversing drug — naloxone — available.²
- As stated by the Centers for Disease Control and Prevention (CDC), “collaboration is essential for success in preventing opioid overdose deaths.”¹
- In an encouraging collaboration, Prime Therapeutics (Prime), a pharmacy benefit manager (PBM) working with Florida Blue and their insured members, identified high-risk opioid utilizers who were filling most of their opioid prescriptions at Walgreens pharmacies.
- A list of identified members was sent to Walgreens so the pharmacist could consult with the patient and provide an Opioid Safety Guide discussing opioid safe use, disposal, storage and the overdose reversal agent naloxone at the next opioid prescription pick up.
- Little is known of the impact a targeted patient Opioid Safety Guide distributed at the pharmacy has on opioid utilization and obtaining naloxone.



Objective

- To assess the impact of the Opioid Safety Guide on naloxone claims and opioid utilization.

Methods


- The study design was a prospective cohort with a concurrent control comparison utilizing administrative pharmacy claims data.
 - The Florida Blue PBM, Prime, identified members during a 3-month period (April – June 2017) who had high opioid and controlled substances utilization and filled most of their opioid claims at either Walgreens pharmacy in Florida (intervention group) or a non-Walgreens retail pharmacy chain in Florida (control group).
 - The list of intervention group members was sent to Walgreens pharmacy chain in July 2017 to provide the Opioid Safety Guide at the member’s next opioid prescription dispensing.
- Study population**
- As an intent-to-treat design, all members identified for the Walgreens intervention, whether or not they receive an Opioid Safety Guide and pharmacist consultation were analyzed. If a member did not receive a consultation, an index date was assigned based on their first opioid claim. If a member did not have an opioid claim, an index date was assigned at random.
 - A control group was created using identical Florida Blue member identification methods for members who filled most of their opioid claims at a non-Walgreens retail pharmacy chain. Member information was not sent to the non-Walgreens retail chain pharmacies.
 - Members were included in the analysis if they had a controlled substance score³ greater than 12 for two consecutive quarters, more than one opioid claim, and were continuously enrolled during a 180-day pre- and post-period.
 - Opioid claims were identified by Generic Product Identifier (GPI) from the Pharmacy Quality Alliance (PQA)’s list of opioids.⁴
 - A pre-post difference-in-difference analysis was implemented to examine the intervention group’s change in study outcomes from the pre-index (baseline) period to the post-index period and compared them to changes in the control group.⁵

Outcomes measurement

- Naloxone claims in all forms were compared in the pre-period versus the post-period.
- Opioid utilization was assessed by opioid discontinuation, morphine milligram equivalents (MME), and overall opioid claim count. MME was calculated using the Centers for Medicare & Medicaid Services (CMS) overutilization monitoring system (OMS) method. Note: all buprenorphine products were excluded.^{6,7}
- Opioid discontinuation was defined by a member who did not have opioid drug supply in the last 45 days at the end of the post-period.
- Overall opioid claim count was assessed by the average number of claims per member in the pre- versus post-period.
- Average number of opioid prescribers per member and whether a member had a long acting opioid claim were also examined.
- SAS 9.4 (SAS Institute Inc., Cary, NC) was used for all analyses.
- Generalized linear models were fit to measure the outcome changes in the 180 days post-index date (follow up) compared to the 180 days pre-index date between the intervention and control group members, with adjustment for age, gender, Charlson Comorbidity Index score and ZIP code derived sociodemographics.
- Statistical significance for all analysis was set at $p < 0.01$.

Results

Figure 1. Members with a Naloxone Claim




- This pilot program began Aug. 15, 2017 with 59 percent of the initial consultations occurring in the first two weeks of program launch. The program has continued with monthly identifications sent to Walgreens pharmacies.
- After all analytic criteria were applied, the intervention group consisted of 753 members and there were 633 members in the control group (Figure 2).
- A total of 578 (77%) of 753 members in the intervention group received a pharmacist consultation and Opioid Safety Guide from Aug. 15, 2017 – Nov. 15, 2017.
- An identical 87% of members in the intervention and control groups had an opioid claim in the post period (Figure 2).
- Baseline characteristics between the intervention and control groups were similar (Table 1).
- Opioid discontinuation was 21.7% for the intervention group compared to 18.5% for controls, $p = 0.13$. The adjusted odds of discontinuation were non-significant (Table 2).
- The intervention group had an additional 25 members with a paid naloxone claim in the 180-day post period compared to no change in the control group, $p < 0.01$ (Figure 1 and Table 2).
- The odds of a member receiving a naloxone claim were 3.98 (1.42 to 11.18) times higher compared to controls, adjusting for baseline characteristics (Table 3).

Conclusions

- This study found a 4-fold increase in odds of a member receiving naloxone, consistent with the U.S. Surgeon General’s Advisory recommending naloxone access for high dose opioid utilizers.²
- Results suggest the collaboration was impactful between a health insurer, pharmacy benefit manager and chain pharmacy to identify high dose opioid utilizers and message them with an Opioid Safety Guide at prescription pick up.
- Additional work is needed to determine successful opioid dose reduction interventions.

Figure 2. Analysis Population Identification



Limitations

- Administrative pharmacy claims have the potential for miscoding and include assumptions of member’s actual opioid use.
- Identification incorporated controlled substance score users which is not limited to opioid use.
- Not all members in the intervention group received a pharmacist consultation.
- It is unknown what opioid specific pharmacist patient counseling was or was not being provided in the control population.
- This study was unable to control for external factors that may have influenced naloxone or opioid prescribing, however, Florida Blue commercially insured opioid users were assessed in both the intervention and control group. These members would have identical benefit designs and are under the same state controlled substance rules, particularly for naloxone prescribing.

Table 1. Baseline Characteristics: Intervention and Control Groups Pre- versus Post-Period 180-day Change

Characteristics (at a member level)	Intervention (n = 753)	Control (n = 633)
Age, average in years (SD)	48.3 (±10.7)	49.5 (±10.5)
Gender (% Female)	491 (65.2%)	417 (65.9%)
Charlson Score at index date	0.4 (±1.2)	0.6 (±1.4)
ZIP code derived		
median household income	\$54,344	\$55,044
% high school degree	88.4%	88.4%
% race white	80.7%	82.5%

SD = standard deviation

Table 2. Unadjusted Outcomes: Intervention and Control Groups Pre- versus Post-Period 180-day Change

Outcomes (at a member level)	Intervention (n = 753)			Control (n = 633)		
	180 day pre-period	180 day post-period	Unadjusted change	180 day pre-period	180 day post-period	Unadjusted change
Naloxone member claim (yes/no)*	3 (0.4%)	28 (3.7%)	+25	6 (0.9%)	6 (0.9%)	0
Overall opioid claims per member	9.4 (±4.8)	8.1 (±5.6)	-1.3	9.8 (±4.7)	8.6 (±6.0)	-1.3
Average MME	81.9 (±112)	78.7 (±112)	-3.2	95.2 (±132)	87.9 (±128)	-7.3
Average number of opioid prescribers	2.6 (±1.6)	1.8 (±1.0)	-0.8	2.6 (±1.6)	1.8 (±1.3)	-0.9
Long acting opioid claim (yes/no)	249 (33.2%)	242 (32.6%)	-7	212 (33.6%)	202 (32.0%)	-10
Opioid discontinuation (defined no opioid drug supply in 45 days at the end of the post period)	163 (21.7%)			117 (18.5%)		

MME = Morphine milligram equivalents
*p < 0.01

Table 3. Adjusted Outcomes: Logistic Regression — 180 day Results

Outcome	Estimate (99% confidence interval)	Intervention group, change pre to post period compared to controls	P value
Member claim for naloxone (yes/no)	Odds ratio difference	3.90 (1.42–11.18)	p < 0.01
Opioid discontinuation	Odds of discontinuation	1.18 (0.83–1.70)	p = 0.23

Model was controlled for baseline member characteristics

References

- CDC (Centers for Disease Control and Prevention). Understanding the Epidemic. <https://www.cdc.gov/drugoverdose/epidemic/index.html>. August 2018.
- U.S. Department of Health & Human Services. Surgeon General’s Advisory on Naloxone and Opioid Overdose. <https://www.surgeongeneral.gov/priorities/opioid-overdose-prevention/naloxone-advisory.html>. January 2018.
- Stamer CE, Qiu Y, Karaca-Mandic P, Gleason PP. Association of a Controlled Substance Scoring Algorithm with Health Care Costs and Hospitalizations: A Cohort Study. *JGIM*. 2016; 22 (12): 1403-1410.
- Pharmacy Quality Alliance (PQA) performance measures. <https://pqaalliance.org/measures/default.asp>.
- Weiss, R.E. Modeling Longitudinal Data. New York, New York: 2005.
- CDC (Centers for Disease Control and Prevention). Calculating Total Daily Dose of Opioids for Safer Dosage. https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf. July 2017.
- CMS (Centers for Medicare and Medicaid Services). Opioid Morphine Milligram Equivalent (MME) Conversion Factors. <https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Opioid-Morphine-EQ-Conversion-Factors-vFeb-2018.pdf>. August 2017.

